From GlobeNewswire:

Pharming Group N.V. reported a 19% increase in total revenues for full year 2023 to US$245.3 million, with record fourth quarter RUCONEST® revenues of US$73.3 million. The company also saw strong early traction for Joenja® (leniolisib) with 81 patients on paid therapy in the U.S. and full year 2023 revenues of US$18.2 million. Cash and marketable securities increased to US$215.0 million, and a 2024 total revenue guidance of US$280 million – US$295 million was provided. Pharming plans to further develop leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling.

Chief Executive Officer Sijmen de Vries commented on the company’s excellent year, with 10% growth in RUCONEST® revenues and the successful launch of Joenja® in the U.S. Pharming identified over 840 APDS patients globally, with efforts ongoing to diagnose more patients and expand leniolisib’s market reach. Regulatory and clinical progress for leniolisib in key markets like Europe, U.K., Japan, Asia Pacific, Middle East, and Canada were highlighted, with plans to start a Phase 2 clinical trial for PIDs with immune dysregulation linked to PI3Kδ signaling.



Read more at GlobeNewswire:: Pharming Group reports fourth quarter and full year 2023